NDATOPICALSYSTEM
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
LICART (diclofenac epolamine) by IBSA Institut Biochimique is analgesic, anti-inflammatory, and antipyretic properties. Approved for soft tissue injuries, acute back strain. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LICART is a topical transdermal system containing diclofenac epolamine, a nonsteroidal anti-inflammatory drug (NSAID) approved by the FDA in December 2018. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes to reduce prostaglandin synthesis, thereby providing analgesic, anti-inflammatory, and antipyretic effects at the site of application. The formulation includes heparin sodium as an inactive ingredient and does not meaningfully affect systemic coagulation at therapeutic doses. LICART is positioned as a topical alternative to oral NSAIDs for localized pain and inflammation management.
$0.0BPart D
8.8 years to LOEMechanism of Action
analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac…
Indications (2)
Worked on LICART at IBSA Institut Biochimique? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.